Tanzeum (Albiglutide): A Once-Weekly GLP-1 Receptor Agonist Subcutaneous Injection Approved for the Treatment of Patients with Type 2 Diabetes

Am Health Drug Benefits. 2015 Mar;8(Spec Feature):126-30.